UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
May 28, 2003
(Date of earliest event reported)
PHARMCHEM, INC.
(Exact name of registrant as specified in its charter)
DELAWARE | 0-19371 | 77-0187280 | ||
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
4600 N. Beach Street, Haltom City, Texas | 76137 | |||
| (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code: 817-605-5300
Item 5. Other Events and Regulation FD Disclosure.
On May 28, 2003, PharmChem, Inc. announced that it had received a Nasdaq Staff Determination Letter. A copy of the press release is attached as Exhibit 99.1 to this Form 8-K.
Item 7. Financial Statements and Exhibits.
(c) Exhibit 99.1. Press release dated May 28, 2003
| Exhibit Index | |||
| 99.1 | Press release dated May 28, 2003 | ||
SIGNATURE
Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| PHARMCHEM, INC. (Registrant) | ||
| May 29, 2003 (Date) | /s/ DAVID A. LATTANZIO David A. Lattanzio Vice President and Chief Financial Officer |
